Evaluating Next Steps for Entrectinib in ROS1-Positive NSCLC
Robert C. Doebele, MD, PhD, shares his thoughts on what the next steps are for entrectinib in patients with <em>ROS1</em>-positive non–small cell lung cancer. In August of 2019, the FDA granted approval to this agent as treatment of patients with metastatic NSCLC who are <em>ROS1</em>-positive.
Robert C. Doebele, MD, PhD, an associate professor in the Division of Medical Oncology at the School of Medicine, University of Colorado, shares his thoughts on what the next steps are for entrectinib (Rozlytrek) in patients withROS1-positive nonsmall cell lung cancer (NSCLC). In August of 2019, the FDA granted approval to this agent as treatment of patients with metastatic NSCLC who areROS1-positive.
Understanding the mechanisms of resistance to entrectinib is an important next step, says Doebele. Next-generation drugs are being evaluated following failure with entrectinib, such as agents like repotrectinib (TPX-0005). However, understanding the types of resistance we see with entrectinib may further help us understand which drug should follow entrectinib. Doebele says that having new therapies for patients who fail first-line therapies is 1 of the goals in among oncologists who specialize in lung cancer.
In August 2019, entrectinib also received an accelerated approval from the FDA for the treatment of adult and adolescent patients with solid tumors harboring anNRTKgene fusion who have no alternative therapies available. For more information on these approvals of entrectinib: https://www.targetedonc.com/news/fda-approves-entrectinib-for-ros1-nsclc-and-ntrk-solid-tumors
